Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Rochon

Vascular & Interventional Radiology Thornton, CO Medical Doctor

NPI 1598913980 CMS profile 1262133

9441 Huron St, Thornton, CO 80260

Open in the dashboard

General payments

$145,191

341 records reported · program years 2019–2025

Research payments

$425

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,350 paid to institutions, not to them · program year 2025

Through program year 2025, Paul Rochon of Thornton, CO is reported in the CMS Open Payments database as having received $145,191 across 341 general payments and $425 in research payments paid to them. Separately, studies naming them as principal investigator received $1,350 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,016 7
2024 General $28,279 82
2023 General $23,473 82
2022 General $33,090 50
2021 General $12,605 26
2021 Research $425 2
2020 General $3,777 9
2019 General $40,952 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Rochon
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Paul Rochon were reported at $3,016. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Paul Rochon Vascular & Interventional Radiology median Middle half National median
2019 $40,952 $422 $125–$1,555 $163
2020 $3,777 $200 $68–$652 $114
2021 $12,605 $280 $99–$866 $132
2022 $33,090 $433 $137–$1,497 $149
2023 $23,473 $506 $152–$2,019 $160
2024 $28,279 $556 $175–$1,930 $164
2025 $3,016 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $35,303 64 payments
  2. Medtronic, Inc. $32,826 55 payments
  3. AngioDynamics, Inc. $31,726 30 payments
  4. Medtronic Vascular, Inc. $17,443 33 payments
  5. Boston Scientific Corporation $10,724 107 payments
  6. Cook Incorporated $6,620 2 payments
  7. Philips Electronics North America Corporation $6,514 3 payments
  8. Nevro Corp. $1,098 10 payments
  9. Viz.Ai, Inc. $491 5 payments
  10. Inari Medical, Inc. $461 4 payments
  11. Other $1,986 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $60,320 25 payments
  2. Long term medical supply or device loan $30,625 3 payments
  3. Consulting Fee $20,496 17 payments
  4. Food and Beverage $14,972 231 payments
  5. Travel and Lodging $13,878 62 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,000 1 payment
  7. Compensation for serving as faculty or as a speaker for a medical education program $600 1 payment
  8. Honoraria $300 1 payment
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $30,625 3 payments
  2. Indigo $26,303 47 payments
  3. VENASEAL $12,818 26 payments
  4. Concerto $10,415 10 payments
  5. RUBY Coil $7,720 10 payments
  6. (9520) IGT Devices Undivided $6,514 3 payments
  7. Indigo System $5,554 8 payments
  8. ONYX 18 $4,659 8 payments
  9. Cook Medical Filters $4,402 6 payments
  10. MVP $3,289 6 payments
  11. Other $19,600 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $425 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

50

Median for Interventional Radiology: 38

Drug cost

$15,338

Median for Interventional Radiology: $333

Branded share of claims

78%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 23 $15,195
Clopidogrel Clopidogrel Bisulfate Brand 16 $112
Tramadol Hcl Generic 11 $31

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 187 billing codes

Paid by Medicare

$279,183

Of which drugs: $792

Medicare patients

3,086

Average age 75

Services billed

5,293

1,827 women, 1,259 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 42%
Diabetes 40%
Chronic kidney disease 37%
Heart failure 33%
Depression 33%
Atrial fibrillation 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fentanyl citrate, 0.1 mg J3010 Office 12 34 $24
Injection, midazolam hydrochloride, per 1 mg J2250 Office 12 61 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REBLOZYL
  • Celgene Corporation $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

343 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record